Abstract: Disclosed are a fault diagnosis circuit, method and apparatus, and computer readable storage medium. The fault diagnosis circuit includes a safety protection circuit electrically connected to a protected circuit and a diagnosis module electrically connected to the safety protection circuit. The safety protection circuit is configured to perform check operation on stored data in the protected circuit to obtain first check data, perform error injection on second check data corresponding to the stored data, and generate a first check result signal based on the first check data and the second check data after the error injection. The diagnosis module is configured to diagnose faults in the safety protection circuit based on the first check result signal. From embodiments of this disclosure, the safety protection circuit is diagnosed faults through a simple hardware structure, to eliminate the faults based on a diagnosis result, thereby ensuring normal operation of a chip.

Abstract: The disclosure relates to the field of battery charging and swapping technologies, and specifically, to a wheel positioning method and system, a medium, an apparatus, and a battery charging and swapping station. The disclosure aims to resolve the problem of poor applicability of an existing four-wheel positioning method for a battery charging and swapping station.

Abstract: The present invention relates to a method, device and software product for converting data into a data DNA sequence and restoring the DNA sequence library into raw data, and a storage medium for storing the software product. The method for converting data into a data DNA sequence comprises: dividing data into one or more data conversion units, providing a binary sequence for each data conversion unit, and converting each data conversion unit into a data DNA sequence according to a dataDNA sequence conversion rule, thus acquiring a data DNA sequence library, which makes biological storage of data in vivo possible by constructing a data DNA library.

Abstract: The present invention relates to a method, device and software product for converting data into a data DNA sequence and restoring the DNA sequence library into raw data, and a storage medium for storing the software product. The method for converting data into a data DNA sequence comprises: dividing data into one or more data conversion units, providing a binary sequence for each data conversion unit, and converting each data conversion unit into a data DNA sequence according to a dataDNA sequence conversion rule, thus acquiring a data DNA sequence library, which makes biological storage of data in vivo possible by constructing a data DNA library.

Abstract: A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator.

Abstract: A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator.

Abstract: The invention is a method of assessing whether an individual is afflicted with congestive heart failure (CHF) comprising comparing the level of corin or portion thereof in the individual to the level of corin or portion thereof in a control, wherein a decrease in the level of corin or portion thereof in the individual compared to the level of corin or portion thereof in the control indicates that the individual is afflicted with CHF. The methods described herein can be also be used to determine the severity of CHF in an individual, whether an individual's treatment for CHF is effective and whether an individual is at risk of developing CHF.

Abstract: Provided herein are methods of inhibiting agouti or agouti-related protein (AGRP) in a cell or in an individual in need thereof, comprising administering to the cell or the individual an effective amount of an agent that induces corin expression, activity or a combination thereof in the cell or individual. The invention also provides a method of treating obesity in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual. Further provided is a method of treating diabetes type II in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual.

Abstract: A method for assessing heart disease in a subject includes generating an expression profile of at least two or more miRNAs in a sample from the subject. The miRNAs can be selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, hsa-miRNA-29b, has-miRNA-125b, hsa-miRNA145, hsa-miRNA-181b, hsa-miRNA-214, hsa-miRNA-342, hsa-miRNA-378 and combinations thereof.

Abstract: A method is provided to produce biodiesel from algae using a two-stage, autotrophic and heterotrophic cultivations of chlorella for biodiesel production. This method includes a sequence of procedures: cultivating photoautotrophic algae, concentrating cells and then transferring them to a fermentor for heterotrophic cultivation. During the photoautotrophic cultivation stage, the culture is exposed to a light source, such as sunlight with carbon dioxide obtained from a carbon dioxide source or from air. antibacterial agents may be added to prevent contamination from undesired microorganisms. Organic carbons are added during heterotrophic cultivation stage. Fermentation conditions are optimized for maximizing lipid synthesis. High biomass is achieved to about 108 g/L with lipid content reaching about 52% of dry cell weight. After cultivation, biodiesel is made through extraction and transesterification of algae lipids.

Abstract: This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of using these fusion proteins as thrombolytic agents, and processes for synthesizing these fusion proteins are also described herein.

Abstract: A method is provided to produce biodiesel from algae using a strain of microalga chlorella protothecoids, by screening a specific strain with characteristics of high yield of biomass and high oil content, cultivating the screened strain for high-cell-density growth for up to 108 grams of dry cell weight per liter of the suspension in a bioreactor using solutions containing carbohydrates as feed, harvesting and drying the high density cultivated algal cells to extract oil from the dried algal cells, and producing the biodiesel by reaction of catalyzed transesterification using the extracted oil as feedstock.

Abstract: This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.

Abstract: The present invention relates to a corin polypeptide which contains one or more frizzled corin and possesses various activities, including, e.g., serin protease activity and a pro-ANF converting activity, LDLR, SRCR repeats, serine protease catalytic domains such as human and mouse corin. The invention further relates to methods of using such nucleic acids and polypeptides in therapeutics, diagnostics, and research. For example, the nucleic acids and polypeptides of corin can be utilized in methods to identify modulators of its activity, in animal models to mimic human disease, and to treat kidney, cardiovascular, and other conditions in which corin is involved.

Abstract: This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.

Abstract: The present invention relates to a corin polypeptide which contains one or more frizzled corin and possesses various activities, including, e.g., serin protease activity and a pro-ANF converting activity, LDLR, SRCR repeats, serine protease catalytic domains such as human and mouse corin. The invention further relates to methods of using such nucleic acids and polypeptides in therapeutics, diagnostics, and research. For example, the nucleic acids and polypeptides of corin can be utilized in methods to identify modulators of its activity, in animal models to mimic human disease, and to treat kidney, cardiovascular, and other conditions in which corin is involved.

Abstract: The present invention provides modified hepsin molecules, or fragments or derivatives thereof, including those having a substitute activation sequence. The modified hepsin molecules are cleaved at the substitute activation sequence, thereby generating activated modified hepsin molecule, or fragments or derivatives thereof, that exhibit the functional activity of naturally-occurring, wild-type hepsin molecules.

Abstract: This invention provides a novel expression control region isolated from mammalian corin genes. This control region preferentially activates transcription in cardiac cells. Methods and compositions are provided to employ this control region for identification of agents capable of modulating corin expression and for treatment of cardiac disease.

Abstract: The present invention provides a transgenic mouse comprising a disrupted hepsin gene. In particular, the invention provides methods of making the transgenic mouse comprising the disrupted hepsin gene by utilizing a hepsin targeting vector for homologous recombination in mouse embryonic stem cells. Also, nucleotide and amino acid hepsin sequences are disclosed.